ARTICLE | Finance
Foundation validation
How CFF’s $25M award provides validation for Corbus’ approach to CF
February 10, 2018 1:22 AM UTC
The not-for-profit Cystic Fibrosis Foundation is putting its weight behind a new approach to treating CF through a $25 million award to Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP).
Corbus plans to use the award to validate an efficacy signal observed in a Phase II trial of lenabasum (formerly anabasum), an oral synthetic cannabinoid CB2 receptor (CNR2) agonist that targets inflammation associated with CF, regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutation. ...